GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Jazz Pharmaceuticals PLC (STU:J7Z) » Definitions » Short-Term Debt

Jazz Pharmaceuticals (STU:J7Z) Short-Term Debt : €557 Mil (As of Mar. 2024)


View and export this data going back to 2013. Start your Free Trial

What is Jazz Pharmaceuticals Short-Term Debt?

Jazz Pharmaceuticals's Short-Term Debt for the quarter that ended in Mar. 2024 was €557 Mil.

Jazz Pharmaceuticals's quarterly Short-Term Debt declined from Sep. 2023 (€566 Mil) to Dec. 2023 (€555 Mil) but then increased from Dec. 2023 (€555 Mil) to Mar. 2024 (€557 Mil).

Jazz Pharmaceuticals's annual Short-Term Debt increased from Dec. 2021 (€27 Mil) to Dec. 2022 (€29 Mil) and increased from Dec. 2022 (€29 Mil) to Dec. 2023 (€555 Mil).

Jazz Pharmaceuticals Short-Term Debt Historical Data

The historical data trend for Jazz Pharmaceuticals's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Jazz Pharmaceuticals Short-Term Debt Chart

Jazz Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Short-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 30.05 202.48 27.44 29.26 554.74

Jazz Pharmaceuticals Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Short-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 28.95 28.61 566.42 554.74 556.95

Jazz Pharmaceuticals Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Jazz Pharmaceuticals Short-Term Debt Related Terms

Thank you for viewing the detailed overview of Jazz Pharmaceuticals's Short-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Jazz Pharmaceuticals (STU:J7Z) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Jazz Pharmaceuticals PLC (STU:J7Z) » Definitions » Short-Term Debt
Comparable Companies
CYTK EXEL PCVX IONS APLS ASND CERE RVMD BPMC VKTX OCSE:NOVO B VRTX REGN ASX:CSL MRNA XKRX:207940 XKRX:068270 XBRU:UCB XBRU:ARGX BNTX
Traded in Other Exchanges
JAZZ:USA JAZZ:Mexico J7Z:Germany
Address
Waterloo Road, Fifth Floor, Waterloo Exchange, Dublin, IRL, D04 E5W7
Website
https://www.jazzpharmaceuticals.com
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.

Jazz Pharmaceuticals (STU:J7Z) Headlines

No Headlines